AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27380904 — intervention group
Group type: COMPARATOR
Intervention: Catheterized ergonovine provocation test
Number of subjects: 20
Study 27330723 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ipragliflozin
Number of subjects: 171
Study 27330723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 24598046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine (2 mg/kg) and Midazolam (0.5 mg/kg)
Number of subjects: 36
Study 24598046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 36
Study 24598046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine and Midazolam
Number of subjects: 36
Study 23103010 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid plate fixation
Number of subjects: 140
Study 23103010 — intervention group
Group type: COMPARATOR
Intervention: Wire cerclage
Number of subjects: 140
Study 18841327 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oxaliplatin 60 mg/m(2) and 5-fluorouracil 225 mg/m(2) daily throughout radiation therapy
Number of subjects: 14
Study 17548049 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐US pairings
Number of subjects: 42
Study 17548049 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaired/non‐contingent CS and US presentations
Number of subjects: 42
Study 17548049 — intervention group
Group type: COMPARATOR
Intervention: CS‐only
Number of subjects: 42
Study 16032519 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of C-reactive protein (CRP) in asymptomatic subjects at intermediate risk for future coronary events (10-year risk of 10-20%)
Number of subjects: 0
Study 16032519 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging biomarkers including Lipoprotein-associated phospholipase A (2) (Lp-PLA (2))
Number of subjects: 0
Study 12532167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular Brachytherapy
Number of subjects: 0
Study 12532167 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 9806255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg Cetrorelix
Number of subjects: 36
Study 9806255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg Cetrorelix
Number of subjects: 36
Study 9806255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 mg Cetrorelix
Number of subjects: 36
Study 7700286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 114
Study 7700286 — intervention group
Group type: COMPARATOR
Intervention: No myelosuppressive therapy (Control)
Number of subjects: 114
Study 29778918 — intervention group
Group type: EXPERIMENTAL
Intervention: SHUTi (internet-based cognitive behavioral therapy for insomnia)
Number of subjects: 303
Study 29778918 — intervention group
Group type: COMPARATOR
Intervention: Online patient education condition (control)
Number of subjects: 303
Study 27894289 — intervention group
Group type: EXPERIMENTAL
Intervention: PRASE intervention (Patient Reporting & Action for a Safe Environment)
Number of subjects: 0
Study 27894289 — intervention group
Group type: EXPERIMENTAL
Intervention: PRASE intervention
Number of subjects: 0
Study 25369488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus sargramostim
Number of subjects: 245
Study 25369488 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 245
Study 24237188 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-18 at 37.5 mg by mouth two times per day (PO bid) for 3 weeks (induction phase)
Number of subjects: 40
Study 24237188 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-18 at the same dose (37.5 mg PO bid) during the maintenance phase
Number of subjects: 40
Study 24237188 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the maintenance phase
Number of subjects: 40
Study 20958145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (CT) with allopurinol (100‐200 mg/day) and citrate preparation (3 g/day) for 12 weeks
Number of subjects: 70
Study 20958145 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol monotherapy (MT) (100‐200 mg/day) for 12 weeks
Number of subjects: 70
Study 20958145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (CT) with allopurinol and citrate preparation
Number of subjects: 70
Study 20958145 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol monotherapy (MT)
Number of subjects: 70
Study 18289234 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic warmed to 37 degrees C
Number of subjects: 140
Study 18289234 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic stored at room temperature (control group)
Number of subjects: 140
Study 17145540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 31
Study 17145540 — intervention group
Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiation Therapy (3D-CRT)
Number of subjects: 31
Study 12932071 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 15 mg (1.5 mL) in Group P
Number of subjects: 453
Study 12932071 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg in Group M1
Number of subjects: 453
Study 12932071 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg in Group M2
Number of subjects: 453
Study 12932071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg in Group O
Number of subjects: 453
Study 10731452 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based smoking cessation program (bedside counseling + 7 telephone calls over 6 months)
Number of subjects: 100
Study 10731452 — intervention group
Group type: COMPARATOR
Intervention: Minimal care (control group)
Number of subjects: 100
Study 10731452 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-efficacy with no intervention
Number of subjects: 100
Study 9013096 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 11
Study 9013096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1524860 — intervention group
Group type: EXPERIMENTAL
Intervention: Unannounced simulated patient evaluators (SPEs) observing physician practices
Number of subjects: 65
Study 4031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Load-induced perturbations applied to the lower lip during speech tasks.
Number of subjects: 5
Study 4031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Load timing variations within the target interval.
Number of subjects: 5
Study 4031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Afferent information from the perioral region.
Number of subjects: 5
Study 30053431 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a nurse (TB/HIV integration officer) and a lay health worker (TB screening officer) for 24 months
Number of subjects: 3328
Study 29691550 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium ball / titanium cap group (Group A)
Number of subjects: 6
Study 29691550 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium ball / golden cap group (Group B)
Number of subjects: 6
Study 26053341 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA via a thin catheter
Number of subjects: 211
Study 26053341 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (endotracheal intubation during mechanical ventilation)
Number of subjects: 211
Study 23782463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) added to treatment as usual
Number of subjects: 216
Study 23782463 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg OD, increased to 40 mg after 4 weeks) added to treatment as usual
Number of subjects: 216
Study 23782463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron and Simvastatin added to treatment as usual
Number of subjects: 216
Study 23782463 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 216
Study 20230405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m² on days 1, 3, and 5 (arm A)
Number of subjects: 56
Study 20230405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 6 mg/m² on day 1 and 3 mg/m² on day 8 (arm B)
Number of subjects: 56
Study 20230405 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 56
Study 18986292 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded intervention in clinical trials for community-acquired pneumonia
Number of subjects: 0
Study 18986292 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded trials
Number of subjects: 0
Study 18986292 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding of clinical trial participants and study drug assignment
Number of subjects: 0
Study 16902792 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of methylprednisolone injected intramuscularly
Number of subjects: 35
Study 16902792 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 35
Study 12836809 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% and Latanoprost 0.005%
Number of subjects: 0
Study 12836809 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%/Dorzolamide 2%
Number of subjects: 0
Study 10806590 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified FSH (H.P. FSH)
Number of subjects: 20
Study 10806590 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (hMG)
Number of subjects: 20
Study 9017565 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient detoxification
Number of subjects: 101
Study 9017565 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous detox hospitalizations
Number of subjects: 101
Study 9017565 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at outpatient programs
Number of subjects: 101
Study 9017565 — intervention group
Group type: COMPARATOR
Intervention: Histories of violence, use of drugs, or demographic characteristics
Number of subjects: 101
Study 9017565 — intervention group
Group type: COMPARATOR
Intervention: Histories of trauma
Number of subjects: 101
Study 1705921 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 55
Study 1705921 — intervention group
Group type: EXPERIMENTAL
Intervention: Future oriented hypnotic imagery
Number of subjects: 55
Study 1705921 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis condition
Number of subjects: 55
Study 6511541 — intervention group
Group type: COMPARATOR
Intervention: Rest group (no training)
Number of subjects: 10
Study 6511541 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (20-45 min/day at 50-60% Vo2max)
Number of subjects: 10
Study 6511541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study 29696328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle Maneuver (IPM)
Number of subjects: 100
Study 29696328 — intervention group
Group type: COMPARATOR
Intervention: No Pringle Maneuver (NPM)
Number of subjects: 100
Study 27029628 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 45
Study 27029628 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT)
Number of subjects: 45
Study 27029628 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rTMS and CIMT
Number of subjects: 45
Study 27029628 — intervention group
Group type: COMPARATOR
Intervention: Camp alone (no rTMS or CIMT)
Number of subjects: 45
Study 25137864 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity simulation
Number of subjects: 11
Study 25137864 — intervention group
Group type: COMPARATOR
Intervention: Low fidelity simulation
Number of subjects: 11
Study 23544200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 74
Study 23544200 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 74
Study 23544200 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab + Laser
Number of subjects: 74
Study 19669176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram
Number of subjects: 49
Study 19669176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram (TEC)
Number of subjects: 49
Study 19669176 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradia Direct Posterior
Number of subjects: 49
Study 18587620 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg SR, BID)
Number of subjects: 600
Study 18587620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 16998453 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (3 x 1000 mg/day for 8 days)
Number of subjects: 24
Study 16998453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 x 50 mg/day of glucose for 8 days)
Number of subjects: 24
Study 15151735 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 microg IM
Number of subjects: 160
Study 15151735 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 10 IU IV infusion
Number of subjects: 160
Study 15151735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 11283917 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg zoledronic acid
Number of subjects: 280
Study 11283917 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg zoledronic acid
Number of subjects: 280
Study 11283917 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg pamidronate
Number of subjects: 280
Study 11283917 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg zoledronic acid
Number of subjects: 280
Study 11283917 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including 2.0 mg and 4.0 mg zoledronic acid, and 90 mg pamidronate)
Number of subjects: 280
Study 11283917 — intervention group
Group type: COMPARATOR
Intervention: zoledronic acid and pamidronate
Number of subjects: 280
Study 9276357 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus immediate LHRH agonist (androgen suppression)
Number of subjects: 173
Study 9276357 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone with hormonal manipulation at relapse
Number of subjects: 173
Study 8214504 — intervention group
Group type: EXPERIMENTAL
Intervention: New epidural catheter with three lateral eyes
Number of subjects: 200
Study 8214504 — intervention group
Group type: COMPARATOR
Intervention: Current catheter type with three widely spaced lateral eyes
Number of subjects: 200
Study 2885122 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 2885122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 2885122 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 2885122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0
Study 2885122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2885122 — intervention group
Group type: EXPERIMENTAL
Intervention: All beta-adrenoceptor antagonists (except pindolol)
Number of subjects: 0
Study 2885122 — intervention group
Group type: EXPERIMENTAL
Intervention: All beta-adrenoceptor antagonists
Number of subjects: 0
Study 30612482 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (intramuscular injection of 12 mg in two doses with an interval of 24 hours)
Number of subjects: 240
Study 30612482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 30612482 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 240
Study 30306310 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination post treatment
Number of subjects: 178
Study 30306310 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccination group
Number of subjects: 178
Study 27753551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-dissociative dose (0.2 mg/kg) of IV ketamine
Number of subjects: 10
Study 27753551 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 10
Study 24742341 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN (EnligHTN(TM), SJM system) plus usual care
Number of subjects: 240
Study 24742341 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 240
Study 23111973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 40
Study 20142823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement (MMS)
Number of subjects: 96
Study 20142823 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 162 mg
Number of subjects: 96
Study 20142823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 18592623 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy treatment
Number of subjects: 82
Study 18592623 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics (gender, age, years of education, performance status)
Number of subjects: 82
Study 15996074 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/day)
Number of subjects: 52
Study 15996074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 12735425 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied to the face
Number of subjects: 14
Study 12735425 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14
Study 10233206 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified release verapamil p.o. (240 mg) administered in the morning (08:00 h)
Number of subjects: 24
Study 10233206 — intervention group
Group type: COMPARATOR
Intervention: Modified release verapamil p.o. (240 mg) administered in the evening (20:00 h)
Number of subjects: 24
Study 10233206 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterated verapamil i.v. (10 mg) administered in the morning
Number of subjects: 24
Study 10233206 — intervention group
Group type: COMPARATOR
Intervention: Deuterated verapamil i.v. (10 mg) administered in the evening
Number of subjects: 24
Study 9005423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholelithiasis
Number of subjects: 392
Study 9005423 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ulcer dyspepsia
Number of subjects: 392
Study 9005423 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 392
Study 1924426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg E5
Number of subjects: 23
Study 1924426 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg E5
Number of subjects: 23
Study 1924426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study 1924426 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 (2.5 mg/kg and 7.5 mg/kg)
Number of subjects: 23
Study 1924426 — intervention group
Group type: EXPERIMENTAL
Intervention: E5
Number of subjects: 23
Study 6413994 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyclidine
Number of subjects: 36
Study 6413994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30308546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 187
Study 30308546 — intervention group
Group type: COMPARATOR
Intervention: 2L of polyethylene glycol/ascorbic acid (2L-PEG/Asc)
Number of subjects: 187
Study 30308546 — intervention group
Group type: EXPERIMENTAL
Intervention: OSS
Number of subjects: 187
Study 30308546 — intervention group
Group type: COMPARATOR
Intervention: 2L-PEG/Asc
Number of subjects: 187
Study 28006816 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 28006816 — intervention group
Group type: COMPARATOR
Intervention: cfDNA positivity (cfDNA+)
Number of subjects: 0
Study 28006816 — intervention group
Group type: COMPARATOR
Intervention: cfDNA detection rates
Number of subjects: 0
Study 27423195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Number of subjects: 56
Study 27423195 — intervention group
Group type: COMPARATOR
Intervention: CT Navigation
Number of subjects: 56
Study 24445092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mL contrast agent
Number of subjects: 51
Study 24445092 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 mL contrast agent
Number of subjects: 51
Study 24445092 — intervention group
Group type: COMPARATOR
Intervention: 1.2 mL contrast agent
Number of subjects: 51
Study 22551576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 84
Study 22551576 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 84
Study 20447259 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with metronidazole (MTZ) 400 mg 3 x per day and amoxicillin (AMX) 500 mg 3 x per day for 14 days
Number of subjects: 30
Study 20447259 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30
Study 20447259 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with MTZ and AMX
Number of subjects: 30
Study 18799768 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute behavioral intervention
Number of subjects: 924
Study 18799768 — intervention group
Group type: COMPARATOR
Intervention: Didactic control condition
Number of subjects: 924
Study 15990456 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN α‐2b plus a standard or weight‐based dose of ribavirin
Number of subjects: 50
Study 11817616 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity exercise performed just prior to depressurization
Number of subjects: 20
Study 11817616 — intervention group
Group type: COMPARATOR
Intervention: Longer rest intervals prior to depressurization
Number of subjects: 20
Study 9887160 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention consisting of three small-group sessions (3-4 hours each)
Number of subjects: 617
Study 9887160 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling about sexually transmitted diseases (Control)
Number of subjects: 617
Study 7725889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (20 mg) in group A
Number of subjects: 90
Study 7725889 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (50 mg) in group A
Number of subjects: 90
Study 7725889 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (150 micrograms) in group A
Number of subjects: 90